FTC v. Amare Global in 2026: Supplement Mental-Health Claims, Children and the Brand-Partner Liability Warning

What the FTC Alleged and Why It Matters

On June 2, 2026, the Federal Trade Commission announced an enforcement action against dietary-supplement company Amare Global Holdings Inc. and three of its principals, alleging that they made false, misleading and unsubstantiated claims about the health benefits of supplements marketed for children and adults. The products named include Kids Happy Juice, Kids Mood+ and the Happy Juice Product Pack, and the FTC alleges the defendants claimed these could improve or treat mental-health conditions including depression, anxiety and ADHD. These are allegations the FTC is pursuing; they have not been finally adjudicated, and this guide treats them as such.

The action matters to advertisers well beyond the supplement industry because it is built entirely on standing legal principles rather than any new rule. The FTC's case rests on the requirement that objective health claims be supported by competent and reliable scientific evidence, on the prohibition of deceptive earnings claims, and on the principle that a company is responsible for what its brand partners say on its behalf. Every social-selling, affiliate and creator-driven brand faces the same three rules, which is why the case reads as a warning rather than a niche supplement story.

"Companies cannot make health claims about their products without competent and reliable scientific evidence to back them up, and they certainly cannot promise that their products will treat serious conditions in children.
— Federal Trade Commission, on supplement health-claim enforcement"

This guide separates the health-claim substantiation issue, the heightened sensitivity of claims about children, the deceptive-earnings dimension, and the brand-partner liability lesson, and translates each into a compliance practice. For the sector framework see the healthcare social-media compliance guide, and for the endorsement rules the FTC endorsement and reviews guide.

Health Claims and the Substantiation Standard

The core of the case is substantiation. Under FTC standards, any objective claim about what a product does — and especially any claim that it treats, cures, mitigates or prevents a health condition — must be supported by competent and reliable scientific evidence at the time the claim is made. The FTC alleges Amare lacked that support for its mental-health claims.

The Claim-Risk Hierarchy

Two points from the case generalise. First, describing a supplement as able to treat a diagnosable condition such as depression, anxiety or ADHD crosses from a structure/function claim into a disease-treatment claim, which demands clinical-grade evidence and can also imply the product is functioning as an unapproved drug. Second, establishment phrasing — "clinically proven", "scientifically backed" — raises rather than lowers the bar, because it represents that specific proof exists and must be matched by that proof. The safe practice is to make only claims the evidence actually supports, and to avoid disease language entirely unless the product is a properly approved treatment. Screen claim language before publication with the Keyword Risk Checker, and for the medicines-advertising overlay see the healthcare and medicines advertising guide.

Claims About Children and Mental Health

The dimension that most sharply distinguishes this case is that several products were marketed for children, and the alleged claims reached children's mental health — including, the FTC alleges, that products could reduce the risk of suicide in children. Claims of this kind occupy the most sensitive corner of advertising law, combining the highest evidentiary bar with the greatest potential for harm.

Why Child-Directed Health Claims Carry Extreme Risk

• Vulnerable audience: claims aimed at parents about children's health conditions target a highly motivated, vulnerable decision, which regulators scrutinise closely.
• Serious conditions: depression, anxiety, ADHD and suicide risk are serious diagnosable conditions, so claims to affect them are disease-treatment claims of the most demanding kind.
• Delayed real treatment: the harm is not only financial — a claim that a supplement addresses a child's mental-health condition can lead a family to delay effective care.

For any brand whose products touch children, the lesson is to hold child-directed claims to the strictest interpretation and to avoid entirely any claim that a non-drug product treats or mitigates a child's mental-health condition. This is an area where the reputational and legal downside so far outweighs any marketing benefit that the only defensible position is to not make such claims. The heightened sensitivity also intersects with children's privacy and advertising rules more broadly. For that context see the COPPA amendments guide and the healthcare compliance guide.

Deceptive Earnings Claims in Social Selling

Alongside the health claims, the FTC alleges Amare made deceptive earnings claims about the money brand partners could make selling its products — for example that anyone could join and earn stated amounts such as a set monthly figure, or supplement or replace their income, regardless of experience or audience. This is a distinct violation that applies to any multi-level, affiliate or referral structure, independent of the health-claim issue.

The Earnings-Claim Rules

• Truthful and typical: income representations must be truthful and reflect what participants typically achieve, not a best-case or aspirational figure presented as normal.
• No unfounded guarantees: claims that "anyone can earn" a specific amount, without regard to effort, skill or market, are the classic deceptive-earnings pattern.
• Substantiation and disclosure: objective income claims need substantiation, and material limitations must be disclosed rather than hidden.

Deceptive-earnings enforcement has been a sustained FTC priority, and social selling amplifies the exposure because brand partners frequently post income screenshots, lifestyle content and recruitment pitches that imply easy earnings. A brand that supplies or encourages such representations, or looks the other way while partners make them, carries the risk. Controlling income messaging — providing accurate typical-results information, prohibiting unfounded guarantees, and monitoring partner posts — is as important as controlling product claims. For how affiliate and partner conduct becomes brand liability, see the affiliate and partner-liability guide.

Brand-Partner and Distributor Liability

The through-line of the case is that the claims at issue were made not only by the company but through its brand partners — the distributors and promoters who sell and market the products, largely on social media. The FTC's action reflects a settled principle that a company is responsible for the claims made on its behalf, which means brand-partner content is the brand's own exposure, not a separate problem belonging to the individual poster.

Where Brand Liability Attaches

The practical implication is that a brand using distributors, affiliates or creators must actively govern what they say: provide a clear list of permitted and prohibited claims, prohibit disease and child-mental-health claims outright, supply accurate income information and ban unfounded guarantees, require clear disclosure of the material connection, and monitor partner content with a process to correct or remove violations. Passivity is not a defence — the case underscores that the brand's failure to control partner claims is itself the exposure. Because two individuals were reportedly already under prior FTC orders, the case also shows that repeat conduct escalates. Verify partner disclosures with the Disclosure Checker, and track enforcement developments on the Policy Change Tracker.

Health and Social-Selling Compliance Checklist

• [ ] Substantiated every objective health claim with competent and reliable scientific evidence before publication
• [ ] Removed all disease-treatment claims for non-drug products (treat, cure, mitigate, prevent)
• [ ] Eliminated any claim that a product treats or mitigates a child's mental-health condition
• [ ] Verified that "clinically proven" and "scientifically backed" phrasing matches actual evidence
• [ ] Provided brand partners with an approved-claims list and prohibited-claims list
• [ ] Replaced income guarantees with accurate typical-results information
• [ ] Required clear disclosure of material connections in partner contracts
• [ ] Implemented monitoring of brand-partner social content with a correction process
• [ ] Confirmed no prior FTC orders bind the company or its principals
• [ ] Confirmed current FTC health-claim and endorsement standards against official sources